Ligand Pharmaceuticals (LGND) Restructuring Costs (2012 - 2016)

Ligand Pharmaceuticals has disclosed Restructuring Costs across 5 years of filings, most recently posting $374000.0 for Q2 2016.

• Restructuring Costs for Q2 2016 came in at $374000.0, up 71.56% year-over-year; the trailing twelve-month figure through Jun 2016 was $1.2 million (up 1.01% YoY), and the FY2016 annual result was $1.0 million, up 1.18% from the prior year.
• Restructuring Costs came in at $374000.0 for Q2 2016 at Ligand Pharmaceuticals, up from $244000.0 in the prior quarter.
• In the past five years, Restructuring Costs ranged from a high of $562000.0 in Q4 2014 to a low of $44000.0 in Q2 2013.
• The 5-year median for Restructuring Costs is $223000.0 (2015), against an average of $248058.8.
• Across the five-year window, Restructuring Costs tumbled 89.37% in 2013 and surged 209.09% in 2014, its largest moves.
• Ligand Pharmaceuticals' Restructuring Costs stood at $356000.0 in 2012, then tumbled by 43.54% to $201000.0 in 2013, then jumped by 179.6% to $562000.0 in 2014, then slumped by 58.36% to $234000.0 in 2015, then soared by 59.83% to $374000.0 in 2016.
• The last three Restructuring Costs figures came in at $374000.0 (Q2 2016), $244000.0 (Q1 2016), and $234000.0 (Q4 2015), per Business Quant data.